These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The influence of arachidonic acid metabolites on PPAR and RXR expression in bovine uterine cells. Szczepańska AA; Łupicka M; Socha BM; Korzekwa AJ Gen Comp Endocrinol; 2018 Jun; 262():27-35. PubMed ID: 29510153 [TBL] [Abstract][Full Text] [Related]
23. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes. Ibabe A; Herrero A; Cajaraville MP Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169 [TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Grygiel-Górniak B Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207 [TBL] [Abstract][Full Text] [Related]
28. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Schoonjans K; Martin G; Staels B; Auwerx J Curr Opin Lipidol; 1997 Jun; 8(3):159-66. PubMed ID: 9211064 [TBL] [Abstract][Full Text] [Related]
29. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Keller H; Givel F; Perroud M; Wahli W Mol Endocrinol; 1995 Jul; 9(7):794-804. PubMed ID: 7476963 [TBL] [Abstract][Full Text] [Related]
30. [PPARs: structure, mechanisms of action and control. Note I]. Filip-Ciubotaru F; Foia L; Manciuc C; Grigore C Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):477-84. PubMed ID: 21870744 [TBL] [Abstract][Full Text] [Related]
31. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials. Arck P; Toth B; Pestka A; Jeschke U Biol Reprod; 2010 Aug; 83(2):168-76. PubMed ID: 20427759 [TBL] [Abstract][Full Text] [Related]
32. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Plutzky J Circ Res; 2011 Apr; 108(8):1002-16. PubMed ID: 21493923 [TBL] [Abstract][Full Text] [Related]
33. Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. Komar CM Reprod Biol Endocrinol; 2005 Aug; 3():41. PubMed ID: 16131403 [TBL] [Abstract][Full Text] [Related]
34. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Crowe DL; Chandraratna RA Breast Cancer Res; 2004; 6(5):R546-55. PubMed ID: 15318936 [TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptors in the cardiovascular system. Bishop-Bailey D Br J Pharmacol; 2000 Mar; 129(5):823-34. PubMed ID: 10696077 [TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptors and the control of inflammation. Cabrero A; Laguna JC; Vázquez M Curr Drug Targets Inflamm Allergy; 2002 Sep; 1(3):243-8. PubMed ID: 14561188 [TBL] [Abstract][Full Text] [Related]
37. The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome. Psilopatis I; Vrettou K; Nousiopoulou E; Palamaris K; Theocharis S J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109247 [TBL] [Abstract][Full Text] [Related]
38. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors. Yumuk VD Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746 [TBL] [Abstract][Full Text] [Related]
39. The Role of PPARs in MDR - a lesson from embryonic development. Konieczna A; Lichnovka R; Erdosova B; Ehrmann J Neoplasma; 2009; 56(4):279-83. PubMed ID: 19469651 [TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment? Weindl G; Schäfer-Korting M; Schaller M; Korting HC Drugs; 2005; 65(14):1919-34. PubMed ID: 16162018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]